Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma
about
Bortezomib for the treatment of multiple myelomaMultiple myeloma in the very elderly patient: challenges and solutionsSubcutaneous Administration of Bortezomib: A Pilot Survey of Oncology NursesSpotlight on ixazomib: potential in the treatment of multiple myelomaClinical use of proteasome inhibitors in the treatment of multiple myelomaCurrent and emerging therapies in mantle cell lymphoma.A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaA phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaSubcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathyPeripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma.Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib.Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.Subcutaneous bortezomib: in multiple myeloma.Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.An analysis of the safety profile of proteasome inhibitors for treating various cancers.Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.Safety of proteasome inhibitors for treatment of multiple myeloma.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.An Overview of Bortezomib-Induced NeurotoxicitySubcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.Characterization of a rat model of bortezomib-induced painful neuropathy.Proteasome-associated deubiquitinases and cancer.The proteasome and proteasome inhibitors in multiple myeloma.Bortezomib for the treatment of multiple myeloma.
P2860
Q24185881-42DDC985-F2F7-4DF3-935D-25E5D085E78FQ26752991-EDE7488F-D1C3-4A34-9223-7547C365E79EQ26771947-C1A16136-7347-459F-8796-D3E41AFCD16CQ26774440-9E8E8404-4A63-43D9-81F5-B5F0FB2D13BCQ28080999-6DB06822-DF10-4909-90F8-1B153F6329D9Q30456545-0985DC1C-4D54-4746-813B-128A4F25B2ADQ33402536-ABB8C65D-8016-4AD7-A492-F4553F71131BQ33404348-B2BA8F89-949B-4A1B-BF59-6F8F6C784A19Q33404749-1106FC03-1D81-4BEB-A2E0-7AFA1CE0CB59Q33405134-B8283A10-D5BB-4A8A-8C0E-55705FE9A204Q33408056-1D2F3D97-F650-4138-8666-6889755943A8Q33412684-563F24D6-22D0-4B5D-8A31-46DA070B795AQ33422017-6FE47C54-7735-4887-89B6-32198000D36DQ33437045-1D80C56F-368F-4CBE-998F-E80D843898A4Q33440605-30EDB299-4B19-451A-971D-BA3BB0D3E56CQ33885696-2488C7DE-90EC-400D-8ED0-5BE5966A5ED3Q34798095-EB6E695F-55CE-4BB9-A9AC-B2E781500723Q34990174-204F3862-A309-4409-827B-19B16E64D41BQ35800851-A4F9D9FB-18B9-46DD-AC45-1788F80CC01EQ35827701-EB988A5E-343D-4ACD-8B04-B4060D54B4A2Q36037229-0407782F-DEBB-4F4B-8DFA-68ED6FD77BF7Q36302859-DFA9B54F-B92F-45E5-BD03-28528051FFC3Q37064721-11C89932-4225-48E0-89BC-E25443622896Q37373159-44DC0051-897A-48F1-A5B3-3EB89062D0E9Q38075800-CA89725D-CA51-4CA8-B2EC-6B4C9EEF2097Q38164689-2BD00B21-A620-418D-906C-D00A1148D3B1Q38227506-7EB02620-4D7C-4082-A9FB-78D49BCD645EQ38232055-7C1A4180-1230-4D8E-BF3A-093DDF226494Q38738098-636C0570-60C4-4CC7-B2B3-6B18D68414C2Q38757067-7D876389-1DF1-4E16-AF3D-BD9EFFB383B4Q39007504-2895003A-0FF8-41DC-A28F-3105F83F23B7Q39177792-BBA47B34-FD86-4381-B9E1-CCA4A7155463Q42046604-A045A1D3-6097-46C1-B26C-9B83D195A976Q42335813-E9A68069-5E10-4085-9DA7-134A52FE6326Q42361419-9436BCBE-48BA-41E0-BCE6-24BC0D24CB13Q42573839-95E06686-E9E7-46CC-930F-61A8DFD66AA0Q47120603-6A819F9A-D9B2-4018-A937-5E9F226917C9Q47161331-6CE19877-0B68-4EE5-B706-38E9632137D6Q47339695-3129A4E4-A791-4F22-99E0-E6A52B35CE77Q47604607-3AAE7D5D-E320-44B3-ACD1-B0B47EDFBCFB
P2860
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Updated survival analysis of a ...... with relapsed multiple myeloma
@en
type
label
Updated survival analysis of a ...... with relapsed multiple myeloma
@en
prefLabel
Updated survival analysis of a ...... with relapsed multiple myeloma
@en
P2093
P2860
P1433
P1476
Updated survival analysis of a ...... with relapsed multiple myeloma
@en
P2093
Andrew Cakana
Bertrand Arnulf
Halyna Pylypenko
Helgi van de Velde
Huaibao Feng
Ievgenii Karamanesht
Sebastian Grosicki
William Deraedt
P2860
P304
P356
10.3324/HAEMATOL.2012.067793
P577
2012-06-11T00:00:00Z